10/22/2013 7:01:49 AM
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today provided an update on its third quarter 2013 and recent business activities.
“This quarter, we continued to make good progress across our key value drivers. LINZESS is performing well across the key leading indicators, reinforcing the significant opportunity we see ahead. Our scientists continue to advance the pharmacology of linaclotide and explore its utility more broadly while also progressing our broader pipeline, and our global partners are making important strides in bringing linaclotide to appropriate patients worldwide,” said Peter Hecht, chief executive officer of Ironwood Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
comments powered by